Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12607000259448
Ethics application status
Approved
Date submitted
11/05/2007
Date registered
15/05/2007
Date last updated
18/11/2015
Type of registration
Prospectively registered
Titles & IDs
Public title
The effects of hypertonic fluid administration in patients with severe sepsis or septic shock
Query!
Scientific title
The effects of hypertonic fluid administration on gastrointestinal
perfusion and sublingual microcirculation, in patients with severe
sepsis or septic shock.
Query!
Secondary ID [1]
262235
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Severe sepsis or septic shock
1798
0
Query!
Condition category
Condition code
Blood
1885
1885
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Intervention: iv infusion over 15 minutes of 250 mls hyperhaes (7.2% NaCl [Sodium Chloride] / 6% Hydroxy Ethyl Starch).
Query!
Intervention code [1]
1751
0
Treatment: Other
Query!
Comparator / control treatment
Control: iv infusion over 15 minutes of 500 mls starquin (6% Hydroxy Ethyl Starch).
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
2681
0
Tonometry: Assuming a baseline value of 10 and a standard deviation of 9 mmHg (based on an earlier study), we calculated a sample size of 24 patients to detect an absolute difference between groups in P[g-a]CO2 gap of 12mmHg after the intervention in a two-sided test with an alpha level of 0.05 and power >80%.
Query!
Assessment method [1]
2681
0
Query!
Timepoint [1]
2681
0
Measured at baseline and every 30 minutes for 6 hours
Query!
Secondary outcome [1]
4535
0
Semiquantitative analysis of sublingual microcirculation
Query!
Assessment method [1]
4535
0
Query!
Timepoint [1]
4535
0
Measured at baseline and after 1 hour
Query!
Secondary outcome [2]
4536
0
Haemodynamic parameters (blood pressure, cardiac output).
Query!
Assessment method [2]
4536
0
Query!
Timepoint [2]
4536
0
Measured at baseline and every 30 minutes for 6 hours.
Query!
Secondary outcome [3]
4537
0
Expression of mRNA (TF, IL6, IL8, IL10, CD11b, TGFb, MCP1, MMP9, ICAM1, L-selectin, HILG) measured by realtime polymerase chain reaction (PCR) techniques.
Query!
Assessment method [3]
4537
0
Query!
Timepoint [3]
4537
0
Measured at baseline and after 4, 8, 12, and 24 hours.
Query!
Secondary outcome [4]
276452
0
Systolic and diastolic function as measured with echocardiography.
Query!
Assessment method [4]
276452
0
Query!
Timepoint [4]
276452
0
Measured at baseline and after 1 hour.
Query!
Eligibility
Key inclusion criteria
Patients with severe sepsis or septic shock and need for fluid resuscitation (stroke volume variation > 12% or by clinical judgment)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Pregnancy, hyponatremia (serum sodium level < 130 mmol/l), hypernatremia (serum sodium level > 150 mmol/l), arrhythmias, myocardial infarction < 1 month prior to study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Concealed allocation by sealed opaque envelopes
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation (coin tossing)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Blinded in the study are: assessors, and data analysts
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
14/05/2007
Query!
Actual
22/06/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
19/12/2008
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
24
Query!
Accrual to date
Query!
Final
24
Query!
Recruitment outside Australia
Country [1]
521
0
New Zealand
Query!
State/province [1]
521
0
Waikato
Query!
Funding & Sponsors
Funding source category [1]
2033
0
Charities/Societies/Foundations
Query!
Name [1]
2033
0
Waikato Medical Research Foundation
Query!
Address [1]
2033
0
Peter Rothwell Academic Centre
Private Bag 3200
Hamilton
Query!
Country [1]
2033
0
New Zealand
Query!
Primary sponsor type
Individual
Query!
Name
Dr Frank van Haren
Query!
Address
Department of Intensive Care
Waikato Hospital
Private Bag 3200
Hamilton
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
1841
0
Individual
Query!
Name [1]
1841
0
Prof Jamie Sleigh
Query!
Address [1]
1841
0
Waikato Hospital
Hamilton
Query!
Country [1]
1841
0
New Zealand
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
3765
0
Waikato Hospital
Query!
Ethics committee address [1]
3765
0
Query!
Ethics committee country [1]
3765
0
Australia
Query!
Date submitted for ethics approval [1]
3765
0
Query!
Approval date [1]
3765
0
16/10/2006
Query!
Ethics approval number [1]
3765
0
NTY/06/08/070
Query!
Summary
Brief summary
Patients with severe sepsis (infection) frequently die. Sepsis interferes with the clotting and inflammatory systems and affects the heart, blood pressure as well as tissue oxygenation of the body. Vigorous fluid administration can restore the volume necessary to ensure blood and oxygen are carried around the body but may not be sufficient for good tissue perfusion. Hypertonic fluid which has a higher concentration of salt, is thought to both increase heart function and improve the flow of blood and oxygen into the micro tissues that supply the body. It is also thought to improve immune function. In this study we hope to randomise 24 eligible Intensive Care patients with severe sepsis, into two groups; a control group which will receive 500mls of 6% HES solution and the treatment group which will receive 250mls of Hyperhes hypertonic fluid. A variety of invasive and non-invasive measurements and blood tests will be taken over a six hour period. Demographic data and illness severity scores will be recorded as well as usual haemodynamic measures and recordings for seriously ill patients. Statistical analysis using standard techniques, will be done on SPSS version 10.0 Hyperhes, evaluated in previous studies, is regarded as a safe and well tolerated treatment for shock.
Query!
Trial website
Query!
Trial related presentations / publications
Hypertonic Fluid Administration in Patients With Septic Shock: A Prospective Randomized Controlled Pilot Study. Van Haren FM, Sleigh J, Boerma EC, La Pine M, Bahr M, Pickkers P, van der Hoeven JG. Shock. 2012 March; 37(3): 268-275 The effects of hypertonic fluid administration on the gene expression of inflammatory mediators in circulating leucocytes in patients with septic shock: a preliminary study. Van Haren FM, Sleigh J, Cursons R, La Pine M, Pickkers P, van der Hoeven JG. Annals of Intensive Care. 2011 Nov 1;1(1):44
Query!
Public notes
Query!
Contacts
Principal investigator
Name
27854
0
A/Prof Frank van Haren
Query!
Address
27854
0
ICU, Canberra Hospital
PO Box 11
Woden 2606
Australia
Query!
Country
27854
0
Australia
Query!
Phone
27854
0
+61262442222
Query!
Fax
27854
0
Query!
Email
27854
0
[email protected]
Query!
Contact person for public queries
Name
10940
0
Mary LaPine, research coordinator
Query!
Address
10940
0
Department of Intensive Care
Waikato Hospital
Private Bag 3200
Hamilton
Query!
Country
10940
0
New Zealand
Query!
Phone
10940
0
+64 78398899
Query!
Fax
10940
0
+64 78398912
Query!
Email
10940
0
[email protected]
Query!
Contact person for scientific queries
Name
1868
0
Dr Frank van Haren. MD PhD
Query!
Address
1868
0
ICU, Canberra Hospital
PO Box 11
Woden 2606
Australia
Query!
Country
1868
0
Australia
Query!
Phone
1868
0
+61262442222
Query!
Fax
1868
0
+61262443507
Query!
Email
1868
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Dimensions AI
Hypertonic Fluid Administration in Patients With Septic Shock
2012
https://doi.org/10.1097/shk.0b013e31823f152f
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF